Fujifilm Diosynth forms antibody alliance with Piramal Healthcare

Will simplify the supply chain leading to shorter time to clinic

Fujifilm Diosynth Biotechnologies has entered into a strategic alliance with Piramal Healthcare UK whereby the two firms will offer contract manufacturing of antibody drug conjugates (ADCs), a growing niche in the development of biopharmaceuticals.

Customers will benefit from the experience and assets of both organisations, while simplifying the supply chain and vendor management relationships, leading to shorter time to clinic, the firms say.

For Fujifilm Diosynth Biotechnologies, this is part of an ongoing programme to expand its offering in mammalian-based biopharmaceuticals. The company recently announced an expansion of its cGMP manufacturing facilities at its RTP, US and Billingham, UK sites.

Stephen Taylor, commercial vice president of Fujifilm Diosynth Biotechnologies, said: ‘This strategic alliance with Piramal is an important step for us in bringing a new, high-technology offering to the marketplace.

‘Our customers will benefit from high quality, consistent material, rapid service and shorter logistical chains, saving time on the critical path of drug development.’

Aidan Walker, president of Formulations Services at Piramal said: ‘Fujifilm Diosynth Biotechnologies has a long track-record in delivering successful biologics programmes, and this alliance will combine strengths from both companies for the benefit of our customers, and ultimately patients.’

Companies